| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2000;18:425-428
© 2000 Elsevier Science NL
a Department of Cardio-thoracic Surgery, United Medical and Dental Schools of Guy's and St Thomas’ Hospitals, London SE1 9RT, UK
b The Clinical PET Centre, United Medical and Dental Schools of Guy's and St Thomas’ Hospitals, London SE1 9RT, UK
c Department of Public Health Sciences, United Medical and Dental Schools of Guy's and St Thomas’ Hospitals, London SE1 9RT, UK
Received 7 September 1999; received in revised form 19 June 2000; accepted 12 July 2000.
Corresponding author. Tel. +44-171-955-5000; fax: +44-171-955-4858
e-mail: julian.dussek{at}tebolds.demon.co.uk
Objective: Positron emission tomography (PET) is being increasingly used as an accurate and non-invasive modality in diagnosis, staging and post-therapy assessment in patients with lung cancer. In this study, we examine whether the uptake of [18F]fluorodeoxyglucose (FDG), a marker of increased glucose metabolism in neoplastic cells, is of prognostic value in patients with primary lung cancer. Methods: We have retrospectively analyzed 77 patients (mean age, 63.0 years; male/female ratio, 53:24) with primary lung cancers who underwent whole body and localized thoracic PET as part of their diagnostic and staging procedures prior to consideration of surgical resection. The standardized uptake value (SUV) of injected FDG for each primary lesion was correlated with tumour histology and the patient's clinical outcome. Results: A SUV of 20 or greater was found to be of significant prognostic value. The chance of survival (with 95% confidence intervals (CI)) at 12 months post-surgery for the various SUV groups was as follows: 75.2% (59.6–85.5) for SUV<10; 67.5% (29.0–88.2) for SUV 10–<12; 63.6% (29.7–84.5) for SUV 12–<15; 66.7% (19.5–90.4) for SUV 15–<20; 16.7% (0.01–0.52) for SUV>20. A SUV of 20 or more is associated with a 4.66 times increase in hazard, compared with lower levels of SUV. We found no significant correlation between tumour histology and SUV. Conclusion: We have previously reported on the significant advantages of PET in the staging and surgical care of patients with lung cancer. The present study adds further support for an additional prognostic role for PET in the management of thoracic malignancy as determined by the amount of labelled-FDG taken up by the primary lesion.
Key Words: Lung neoplasm • Positron emission tomography • Surgery • Prognosis
This article has been cited by other articles:
|
|
 |
|
  J. K. Hoang, L. F. Hoagland, R. E. Coleman, A. D. Coan, J. E. Herndon II, and E. F. Patz Jr Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non-Small-Cell Lung Carcinoma J. Clin. Oncol., March 20, 2008; 26(9): 1459 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Downey, T. Akhurst, M. Gonen, B. Park, and V. Rusch Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1419 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Okada, S. Tauchi, K. Iwanaga, T. Mimura, Y. Kitamura, H. Watanabe, S. Adachi, T. Sakuma, and C. Ohbayashi Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber, J. Czernin, and M. E. Phelps Prognostic Significance of Fluorodeoxyglucose Uptake in Non-Small Cell Lung Cancer. A Blurry Picture? Clin. Cancer Res., June 1, 2007; 13(11): 3105 - 3106. [Full Text] [PDF]
|
|
|
|
|
|
H. Vesselle, J. D. Freeman, L. Wiens, J. Stern, H. Q. Nguyen, S. E. Hawes, P. Bastian, A. Salskov, E. Vallieres, and D. E. Wood Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role Clin. Cancer Res., June 1, 2007; 13(11): 3255 - 3263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma Ann. Onc., November 1, 2006; 17(11): 1650 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schimmer, K. Neukam, and O. Elert Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 418 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer J. Nucl. Med., April 1, 2006; 47(4): 559 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Guo, K. Higashi, Y. Ueda, M. Oguchi, T. Takegami, H. Toga, T. Sakuma, H. Yokota, S. Katsuda, H. Tonami, et al. Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas J. Nucl. Med., March 1, 2006; 47(3): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, A. S. Bryant, B. Ohja, and A. A. Bartolucci The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Lindell, T. E. Hartman, S. J. Swensen, J. R. Jett, D. E. Midthun, M. A. Nathan, and V. J. Lowe Lung Cancer Screening Experience: A Retrospective Review of PET in 22 Non-Small Cell Lung Carcinomas Detected on Screening Chest CT in a High-Risk Population Am. J. Roentgenol., July 1, 2005; 185(1): 126 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Shankar and D. C. Sullivan Functional Imaging in Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3203 - 3211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer Chest, November 1, 2004; 126(5): 1656 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Schrevens, N. Lorent, C. Dooms, and J. Vansteenkiste The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer Oncologist, November 1, 2004; 9(6): 633 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D R Baldwin, J D Birchall, R H Ganatra, and K S Pointon Evaluation of the solitary pulmonary nodule: clinical management, role of CT and nuclear medicine Imaging, October 1, 2004; 16(1): 22 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Downey, T. Akhurst, M. Gonen, A. Vincent, M. S. Bains, S. Larson, and V. Rusch Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection J. Clin. Oncol., August 15, 2004; 22(16): 3255 - 3260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Guo, K. Higashi, H. Yokota, Y. Nagao, Y. Ueda, Y. Kodama, M. Oguchi, S. Taki, H. Tonami, and I. Yamamoto In Vitro Proton Magnetic Resonance Spectroscopic Lactate and Choline Measurements, 18F-FDG Uptake, and Prognosis in Patients with Lung Adenocarcinoma J. Nucl. Med., August 1, 2004; 45(8): 1334 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Larson Positron Emission Tomography-Based Molecular Imaging in Human Cancer: Exploring the Link between Hypoxia and Accelerated Glucose Metabolism Clin. Cancer Res., April 1, 2004; 10(7): 2203 - 2204. [Full Text] [PDF]
|
|
|
|
|
|
L. Kostakoglu and S. J. Goldsmith 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 224 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Franzius, S. Bielack, S. Flege, J. Sciuk, H. Jurgens, and O. Schober Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma J. Nucl. Med., August 1, 2002; 43(8): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Marom, S. Sarvis, J. E. Herndon, and E. F. Patz Jr T1 Lung Cancers: Sensitivity of Diagnosis with Fluorodeoxyglucose PET Radiology, May 1, 2002; 223(2): 453 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Higashi, Y. Ueda, Y. Arisaka, T. Sakuma, Y. Nambu, M. Oguchi, H. Seki, S. Taki, H. Tonami, and I. Yamamoto 18F-FDG Uptake as a Biologic Prognostic Factor for Recurrence in Patients with Surgically Resected Non-Small Cell Lung Cancer J. Nucl. Med., January 1, 2002; 43(1): 39 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S F Barrington Whole body applications of positron emission tomography in oncology Imaging, September 1, 2001; 13(3): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
